The effect of coronavirus disease 2019 pneumonia on myocardial ischemia detected by single-photon emission computed tomography myocardial perfusion imaging

Önder Bilge, Halil Kömek, Ferat Kepenek, Ercan Taştan, Cihan Gündoğan, Ismail Tatlı, Cansu Öztürk, Halil Akin, Ferhat Işık, Şeyhmus Kavak, Burhan Aslan, Abdurrahman Akyüz, Neşe Kanbal Çap and Emrah Erdoğan

Objective
We aimed to examine the effects of COVID-19 pneumonia on cardiac ischemia detected by myocardial perfusion imaging with single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in patients presenting with chest pain and shortness of breath after recovery from COVID-19.

Materials and method
Patients with a history of COVID-19 confirmed by reverse transcriptase-PCR test who underwent SPECT-MPI for the evaluation of ischemia with the complaints of chest pain and shortness of breath were screened for this study. Patients who underwent thorax CT during the acute period of the COVID-19 were included. Patients with and without pneumonia were determined based on computed tomographic criteria. The patients with a summed stress score of at least 4 on SPECT-MPI were considered to have abnormal MPI in terms of ischemia.

Results
A total of 266 patients were included in the study. Sixty-five (24%) patients had ischemia findings on SPECT-MPI. Thorax CT showed pneumonia in 152 (57%) patients, and the patients were divided into two groups as pneumonia and nonpneumonia. Abnormal SPECT-MPI scores, which represented myocardial ischemia, were higher in the pneumonia group. Multivariate logistic regression analyses showed that the presence of hyperlipidemia and pneumonia on CT increased the risk of ischemia on SPECT-MPI (OR, 2.08; 95% CI, 1.08–3.99; P-value = 0.029; and OR, 2.90; 95% CI, 1.52–5.54; P-value = 0.001, respectively).

Conclusion
COVID-19 pneumonia was identified as an independent predictor of ischemia on SPECT-MPI. Symptoms including chest pain and shortness of breath in patients who have had COVID-19 pneumonia may be attributed to coronary ischemia. Nucl Med Commun 43: 756–762 Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Keywords: cardiac ischemia, COVID-19, pneumonia, SPECT-MPI

Introduction
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a significant cause of morbidity and mortality worldwide [1]. Along with the escalating number of cases, concerns about long-term sequelae are also growing in patients recovering from COVID-19 [2]. Cardiovascular complications including myocarditis, acute coronary syndrome, thromboembolic events, and arrhythmia may develop in the acute period of COVID-19 [3]. Cardiovascular damage may be directly associated with cardiac and endothelial damage by the virus, or it may occur secondary to cytokine storm, hypercoagulability, and hypoxia [4]. Cardiovascular symptoms such as chest pain, shortness of breath, palpitations, and postural orthostatic tachycardia may be observed in patients recovering from COVID-19. The persistence of these complaints for more than 3 months is defined as chronic or prolonged COVID-19 [5]. Maestrini et al. [6] found that 47.5% of patients had persistent symptoms, with fatigue (14.2%) being the most common complaint, followed by dyspnea (10.8%), palpitations (4.2%), and chest pain (1.7%) during the 1-year follow-up of patients who recovered from COVID-19. Another study found that symptoms persisted in 77.1% of 96 patients after 1 year of follow-up, and the most common complaints were decreased exercise capacity, fatigue, and shortness of breath, in decreasing order [7].

Coronary microvascular dysfunction (CMD) during COVID-19 may arise due to various causes including renin-angiotensin system (RAAS) dysregulation,
endothelial damage, and microthrombi [8]. Persistent chest pain after recovery from COVID-19 has been linked to CMD demonstrated using adenosine stress cardiac myocardial MRI [9]. There is inadequate data on the role of myocardial perfusion scintigraphy in evaluating myocardial ischemia in patients who develop pneumonia during COVID-19. In this study, we aimed to examine the correlation between previous COVID-19 pneumonia and myocardial ischemia using single-photon emission computed tomography (CT) myocardial perfusion imaging (SPECT-MPI) in patients presenting with chest pain, shortness of breath, or both after recovery from COVID-19.

Materials and method
Patients who presented to the cardiology outpatient clinic of our hospital with complaints of chest pain, shortness of breath, or both after recovery from acute COVID-19 and underwent SPECT-MPI between 1 January 2021 and 1 November 2021 were screened for this single-center retrospective study. Patients with a history of critical coronary stenosis, previous coronary revascularization, severe valvular diseases, hypertrophic cardiomyopathy, cardiac failure, and those who could not achieve an optimal MPI were excluded. After exclusion, a total of 266 patients were included in the analyses, 152 of whom had COVID-19 pneumonia on thorax CT. Presence of prior COVID-19 infection was confirmed using a reverse transcriptase-PCR test at the time of initial presentation with COVID symptoms. Presence of more than 50% stenosis in any coronary artery in patients who underwent coronary angiography was defined as critical stenosis. Left ventricular ejection fraction (%) was measured by the Simpson method or visual assessment. Patients’ demographic characteristics, comorbidities, laboratory parameters, and coronary angiography results were collected from the electronic medical records of the hospital and the national electronic medical registry system.

Myocardial perfusion imaging
The 2-day stress-rest protocol was performed on all patients. The stress protocol was applied as pharmacological stress according to the recommendation of the European Association of Nuclear Medicine within the scope of COVID-19 measures. Before the stress study, all patients were asked to interrupt taking dipyridamole and xanthine derivatives 24 h in advance, and tea and coffee 12 h in advance. A 6-min infusion of adenosine at 140 μg/kg/min was administered to all patients with a technetium-99m-methoxyisobutylisonitrile (Tc-99m) MIBI bolus injection of 11 MBq/kg at the third minute of the infusion [10]. The adverse reactions regressed with the discontinuation of the infusion in patients who experienced side effects, and no patient needed an amiphylline infusion. On the next day, the same dose of Tc-99m MIBI bolus injection was administered for the rest imaging. In order to enhance hepatobiliary clearance, patients were given fatty foods like milk and chocolate 15 min after the radiopharmaceutical injection. In addition, gastric distension was ensured with carbonated drinks. SPECT images were acquired with 60 projections at the 9th–13th seconds in every 3° projection using the Step & Shoot method to have an anterior orbit from a 180° 64 × 64 matrices by scanning the area between the 45° right anterior oblique and 45° left posterior oblique projections in L-mode (angle of 90° between collimators) with a low-energy ultrahigh-resolution collimator in the supine position using the GE Orbita NM 640 SPECT-CT instrument (GE Healthcare, Milwaukee, Wisconsin, USA) 30–45 min after injection for stress images and 45–60 min for rest images. Then, low-dose CT (140 keV, 2.5 mAs) images were acquired from the thorax for attenuation correction.

Evaluation of images
All images were processed using the Myovation Evolution Software (OSEM with 12 iterations, 10 subsets) on the Xeleris 2.0 (Xeleris, GE Healthcare, Haifa, Israel) workstation. Motion artifacts, if any, were corrected with the motion correction program. CT images and myocardial perfusion images were automatically corrected using filtered back projection and Butterworth filter (0.4 order 10) after the reconstruction of images by manual overlapping. The reconstructed images with QGS/QPS software (Xeleris, Cedars-Sinai Medical Center, Los Angeles, California, USA) were assessed by a consensus of two experienced nuclear medicine specialists without any clinical information other than the sex, height, and weight of the patients. Myocardial perfusion was assessed using the standard 17-segment myocardial modeling, a visual semiquantitative method [11]. Perfusion was evaluated on a 5-point scale in each segment: 0: normal, 1: mildly reduced, 2: moderately reduced, 3: severely reduced, and 4: absent uptake. After scoring all segments, the summed stress score (SSS), which is the sum of all scores from 17 segments, the summed rest score (SRS), and the summed difference score, which was calculated by subtracting the SSS from the SRS and indicates ischemia, were computed for stress and rest images individually. An SSS of at least 4 was considered abnormal perfusion for MPI. The total perfusion deficit (TPD) was calculated based on both the extent and severity of ischemia and a TPD of at least 10% was considered as abnormal myocardium [12].

Acquisition of thorax computed tomography images and technical parameters
All examinations were performed using 16- and 64-channel multislice CT scanners [Emotion 16, Somatom Sensation 64 (Siemens Healthineers, Erlangen, Germany)]. CT scans were performed in the supine position at the end of deep inspiration without administering a contrast agent. A standard dose or low-dose setting was used with automatic dosing control to have a CT acquisition protocol of 120 kV, 80 mA, and a slice thickness of...
1 mm. Coronal images were obtained by reconstructing the axial images over a slice thickness of 1.5 mm. Window settings for lung parenchyma (window level 600 HU and window width 1500 HU) and mediastinum (window level 40 HU and window width 350 HU) were selected, and shootings were performed. Thorax CT scans were evaluated for parameters associated with COVID-19 disease in the lung parenchyma including ground glass densities, consolidation, nodular densities, cobblesstone appearance, reticulation, subpleural band, interlobular septal thickening, halo and reverse halo signs, enlarged vessel sign at the lesion level, bronchi wall changes, and traction bronchiectasis. Cases with thorax CT findings evaluated in the typical COVID-19 category based on the Expert Consensus Statement of the American College of Radiology and the Radiological Society of North America (RSNA) were considered positive for the radiological findings of COVID-19, whereas those in the atypical category and without infection findings according to the RSNA guidelines were considered negative for the radiological findings of COVID-19 [13]. As per this classification system, cases in the indeterminate group were excluded from the study. The study was approved by the local ethics committee of the institution (approval no: 2022/20). The study protocol is in concordance with the Declaration of Helsinki.

Statistical analysis
The data were analyzed using SPSS-24 (Statistical Package for Social Science for Windows; IBM Corporation, Armonk, New York, USA) package program. Histogram and Shapiro-Wilk tests were used to verify the normality of data. Continuous variables were presented as a median and interquartile range (IQR) (25–75%) owing to their nonnormal distribution. Categorical variables were expressed as percentages. Continuous variables were compared using Mann–Whitney U test, whereas categorical variables were compared using the Chi-square test or Fisher’s exact test. We selected predictive candidate variables that have known or plausible associations with ischemia in SPECT-MPI. These variables (age, sex, hypertension, diabetes, hyperlipidemia, smoking, white blood cell count, creatinine, hemoglobin, C-reactive protein, and pneumonia in thorax CT) were used in regression analyses. Univariable and multivariable logistic regression analyses were performed to determine the predictors of ischemia in SPECT-MPI. Variables with a P-value of <0.200 in univariable analyses were included in the model for multivariable analysis. A P-value of <0.05 was considered statistically significant in all statistical analyses.

Results
A total of 266 patients were included in the study. The median age in the study group was 57 years (IQR, 50–64 years), and 79 (30%) were male. All patients were symptomatic during the acute COVID-19 period and underwent thorax CT. CT revealed COVID-19 pneumonia in 152 (57%) of the patients. Patients were divided into two groups: pneumonia and nonpneumonia. The time from COVID-19 diagnosis to MPI was 154 days (IQR, 81–224). Among these patients, 65 (24%) had ischemia findings on SPECT-MPI (Fig. 1). Coronary angiography was performed in 54 patients, and 11 had at least 50% stenosis (Fig. 2).

There was no statistically significant difference between the groups in terms of age, sex, diabetes, hypertension, hyperlipidemia, and smoking. The SSS and abnormal SPECT-MPI scores in terms of ischemia were higher in the pneumonia group (P-values were 0.002 and 0.017, respectively). Demographic, clinical, and laboratory characteristics of the study population are presented in Table 1.

Pneumonia and hyperlipidemia were found to be predictors of ischemia in the univariable logistic regression analysis (P = 0.012 and P = 0.002, respectively). In the multivariate logistic regression analysis performed with parameters with a P-value of <0.200 in the univariant analysis, it was observed that the presence of hyperlipidemia and pneumonia significantly increased the risk of ischemia in SPECT-MPI [odds ratio (OR), 2.08; 95% confidence interval (CI), 1.08–3.99; P-value = 0.029, and OR, 2.90; 95% CI, 1.52–5.54; P-value = 0.001, respectively] (Table 2).

Discussion
To the best of our knowledge, this is the first study assessing the impact of COVID-19 pneumonia (detected by thorax CT) on myocardial ischemia (detected by SPECT-MPI) in patients with a history of COVID-19 and presented with chest pain, shortness of breath, or both after recovery. In our study, abnormal SPECT-MPI scores were higher in the pneumonia group, reflecting higher rate of ischemia. Furthermore, multivariate logistic regression analysis revealed that the presence of pneumonia and hyperlipidemia augmented the risk of ischemia on SPECT-MPI.

COVID-19, which remains a significant cause of morbidity and mortality around the world, has been found to cause cardiovascular effects in the acute period of the disease as well as an increase in the risk of cardiovascular events in the postacute period. A study showed that the risk of developing myocardial infarction, stroke, heart failure, and arrhythmia increased three-fold in patients recovering from the disease [14]. SARS-CoV-2 can directly cause infection by binding to the transmembrane angiotensin-converting enzyme 2 (ACE2) receptor on the surface of vascular endothelial cells. Therefore, it may result in both endothelial dysfunction and myocardial inflammation/infarction due to atherosclerotic plaque instability and increased vascular inflammation.
and microthrombi [15,16]. In addition to direct endothelial damage, it leads to CMD and further worsens the endothelial damage because of an exaggerated autoimmune response and excessively released proinflammatory cytokines [17]. Indeed, circulating biomarkers showing endothelial dysfunction and damage have been demonstrated to increase in COVID-19 in correlation with the severity of the disease [18,19]. Under normal conditions, in cases of inflammation, there is endothelium-dependent dilation and constriction of coronary
arterioles per myocardial oxygen supply and demand. The coronary microvascular circulatory disorder may arise due to excessive cytokine release, thrombotic microvascular obstruction, and disruption of signaling pathways in smooth muscle cells and endothelium [20]. However, RAAS dysregulation, which contributes to the pathophysiology of CMD, acts by reducing the conversion of angiotensin II (AII) to angiotensin 1–7, with the SARS-CoV-2 virus downregulating ACE2 activity in myocardial and endothelial cells. This reduced activity increases the dominance of the RAAS pathway caused by AII activation, resulting in vasoconstriction, fibrosis, hypertrophy, and the release of reactive oxygen radicals [21]. These pathophysiological changes in the acute period of COVID-19 may have long-term implications for coronary microvascular circulation, even if active inflammation resolves. As autoregulation and modulation of coronary blood flow are impaired in response to different stimuli (such as physical exercise) in CMD, exertional dyspnea and chest pain may be observed [22]. Studies have found that symptoms such as shortness of breath, chest pain, and fatigue may occur after recovery from COVID-19 [23]. A meta-analysis evaluating the cardiac sequelae of 52,906 patients, in which the median time from diagnosis to recovery from COVID-19 was 48 days, showed that 25% of the patients experienced chest pain, 36% had shortness of breath, 15% had pericardial effusion, 40% had diastolic dysfunction on echocardiography, and 10% had late gadolinium enhancement on cardiac MRI [24]. These studies demonstrate that patients recovering from COVID-19 may develop cardiovascular symptoms at a significant rate, even after a long time.

SPECT-MPI is the basic imaging method for coronary ischemia and risk assessment. In an invasive study of CMD by Djăileb et al. [25], it was observed that SPECT-MPI ischemia could be employed as a prognostic factor for microvascular dysfunction and serious cardiac events.

| Variables          | Total (n = 266) | Pneumonia (n = 152) | Nonpneumonia (n = 114) | P-value |
|--------------------|----------------|--------------------|-------------------------|---------|
| Age (years)        | 57 (50–64)     | 58 (50–66)         | 55 (50–63)              | 0.084   |
| Male sex, n (%)    | 79 (30)        | 42 (28)            | 37 (32)                 | 0.094   |
| Hypertension, n (%)| 137 (52)       | 84 (55)            | 53 (46)                 | 0.157   |
| Abnormal MPS, n (%)| 65 (24)        | 48 (32)            | 17 (15)                 | 0.002   |
| Total perfusion defect, n (%) | 33 (12) | 23 (15) | 10 (9) | 0.165 |
| SSS                | 0 (0–3)        | 0 (0–4)            | 0 (0–1)                 | 0.017   |
| Time from COVID-19 diagnosis to SPECT-MPI (day) | 154 (81–224) | 162 (85–230) | 148 (80–210) | 0.172 |
| Diabetes, n (%)    | 80 (30)        | 50 (33)            | 30 (28)                 | 0.247   |
| Smocking, n (%)    | 65 (24)        | 37 (24)            | 28 (25)                 | 0.984   |
| Hyperlipidemia, n (%) | 63 (24) | 36 (24) | 27 (24) | 0.995 |
| Ejection fraction (%) | 60 (60–61) | 60 (60–61) | 60 (60–62) | 0.322   |
| Creatinine, mg/dl  | 0.77 (0.68–0.90) | 0.78 (0.69–0.91) | 0.76 (0.68–0.89) | 0.716   |
| Total cholesterol, mg/dl | 190 (170–221) | 189 (165–219) | 197 (175–221) | 0.244   |
| HDL-cholesterol, mg/dl | 45 (38–54) | 44 (37–54) | 46 (39–55) | 0.370   |
| LDL-cholesterol, mg/dl | 112 (91–133) | 111 (89–130) | 116 (95–137) | 0.184   |
| Triglyceride, mg/dl | 170 (124–228) | 180 (137–226) | 155 (105–226) | 0.056   |
| Hemoglobin, g/dl   | 13.5 (12.5–14.7) | 13.4 (12.5–14.8) | 13.7 (12.5–14.7) | 0.002   |
| White blood cell count, 10^3/µl | 7.71 (6.56–9.00) | 7.80 (6.62–8.90) | 7.65 (6.51–9.10) | 0.819   |
| Platelet, count, 10^3/µl | 271 (217–317) | 273 (224–315) | 271 (217–317) | 0.365   |
| CRP, mg/dl         | 2 (2–6)        | 3 (2–7)            | 2 (2–5)                 | 0.330   |

Bold characters used to indicate statistical significance.
Continuous variables are presented given as median (interquartile range) and categorical variables were expressed as number.
CRP, C-reactive protein; MPS, myocardial perfusion scintigraphy; SPECT-MPI, single-photon emission computed tomography myocardial perfusion imaging; SSS, summed stress score.

| Variables          | Univariable analysis | Multivariable analysis |
|--------------------|---------------------|-----------------------|
|                    | OR 95% CI            | P-value               | OR 95% CI            | P-value               |
| Age (years)        | 0.99 0.96–1.01       | 0.364                 | ND ND ND             |
| Sex (male)         | 1.18 0.64–2.15       | 0.597                 | ND ND ND             |
| Hypertension       | 0.82 0.47–1.43       | 0.480                 | ND ND ND             |
| Diabetes           | 1.66 0.92–2.99       | 0.092                 | 1.70 ND              |
| Hyperlipidemia     | 2.20 1.19–4.08       | 0.012                 | 2.08 1.08–3.99       |
| Smocking           | 1.68 0.91–3.12       | 1.00                  | 1.94 0.97–3.86       |
| Creatinine (mg/dl) | 0.98 0.90–1.06       | 0.565                 | ND ND ND             |
| White blood cell (10^3/µl) | 1.11 0.97–1.28 | 0.140                 | 1.11 0.96–1.29       |
| CRP (mg/l)         | 1.01 0.98–1.07       | 0.641                 | ND ND ND             |
| Hemoglobin (g/dl)  | 1.00 0.84–1.19       | 0.984                 | ND ND ND             |
| Pneumonia          | 2.63 1.42–4.89       | 0.002                 | 2.90 1.52–5.54       | 0.001   |

CI, confidence interval; CRP, C-reactive protein, ND, no data; OR, odds ratio.
in patients without obstructive coronary artery disease. A post-COVID study concluded that persistent chest pain might be due to microvascular dysfunction on adenosine stress cardiac MRI examination [9]. Rovas et al. [18] evaluated patients with dyspnea and post-COVID fatigue syndrome following recovery from COVID-19 and found that the myocardial perfusion reserve was significantly lower on cardiac MRI in the COVID group compared with healthy controls. In our study, the rate of abnormal MPI was significantly higher in the pneumonia group (32%), and we found that the presence of pneumonia in acute period of COVID-19 is a predictor of ischemia on SPECT-MPI. The severity of pneumonia in COVID-19 patients has been found to be associated with cytokine storm, and a higher rate of inflammatory cytokines (IL-1β, IL-6, and IL-8), macrophages, and neutrophils were detected in the bronchoalveolar lavage fluids of patients with severe symptoms than those with mild symptoms [26,27]. Given all these pathophysiological mechanisms, we believe that the presence of pneumonia during the acute period of COVID-19 produces a greater inflammatory response and, therefore, leads to CMD via vascular endothelial damage. This may cause the rates of ischemia on SPECT-MPI to be higher in the pneumonia group.

Chest pain and shortness of breath can be observed in the postacute period of patients with a history of COVID-19. These complaints may be more common in patients with pneumonia, and coronary ischemia may be due to CMD resulting from COVID-19 pneumonia in cases with noncritical epicardial coronary arteries and ischemia detected on SPECT-MPI.

Limitations
One of the most important limitations of this study is that it is a retrospective study with a relatively small number of patients. Another limitation is that family history, which is one of the most important risk factors for coronary ischemia, cannot be included in the regression analysis because the related data was not available for all patients. Also, we could not conduct an invasive assessment of microvascular dysfunction because of the retrospective nature of the study and difficulties in invasive assessment.

Conclusion
In our study, COVID-19 pneumonia was identified as an independent predictor of ischemia on SPECT-MPI. Therefore, symptoms including chest pain and shortness of breath in patients who have had COVID-19 pneumonia may be attributed to coronary ischemia.

Acknowledgements
Conflicts of interest
There are no conflicts of interest.

References
1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20:533–534.
2. Bhata S, Antinone C, Jaffe AS, Gersh BJ, Chandralekaran K, Foley TA, et al. Cardiac magnetic resonance in patients with elevated troponin and normal coronary angiography. Heart 2019; 105:1231–1236.
3. Saeed S, Tadic M, Larsen TH, Grassi G, Mancia G. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. J Hypertens 2021; 39:1282–1292.
4. Eros R, Barreiro-Pérez M, Martín-García A, Armeida J, Villacorta E, Pérez-Pons P, et al. Afección pericárdica y miocárdica tras infección por SARS-CoV-2: estudio descriptivo transversal en trabajadores sanitarios [Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers]. Rev Esp Cardiol 2022 [Epub ahead of print].
5. Árvalos V, Ortega-Paz L, Rodríguez-Arias JJ, Calvo López M, Castrillo-Golano L, Salazar-Rodriguez A, et al. Acute and chronic effects of COVID-19 on the cardiovascular system. J Cardiovasc Dev Dis 2021; 8:128.
6. Maestri V, Birtolo Li, Francone M, Galardo G, Gales N, Severino P, et al. Policlinico Umberto I COVID-19 Group. Cardiac involvement in consecutive unselected hospitalized COVID-19 population: in-hospital evaluation and 1-year follow-up. Int J Cardiol 2021; 339:335–342.
7. Seebel J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lin A, et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis 2022; 74:1191–1198.
8. Yin J, Wang S, Liu Y, Chen J, D U, Xu T. Coronary microvascular dysfunction pathophysiology in COVID-19. Microcirculation 2021; 28:e12718.
9. Vallejo N, Teis A, Mateu L, Bayés-Genís A. Persistent chest pain after recovery of COVID-19: microvascular disease-related angina? Eur Heart J Case Rep 2021; 5:yta105.
10. Verbeemen HJ, Acampa W, Anagnostopoulos C, Ballinger J, Benger J, De Bondt P, et al; European Association of Nuclear Medicine (EANM). EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging 2015; 42:1929–1940.
11. Cerqueira MD, Weissman NJ, Dilisizian V, Jacobs AK, Kaul S, Laskey WK, et al; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539–542.
12. Csiga M, Wygoda Z, Dusziewska A, Szczepaniak AG, Glowacki J, Gąsior M, Wasilewski JP. Interpreting myocardial perfusion scintigraphy using single-photon emission computed tomography. Part 1. Kardiochir Torakochirurgia Pol 2017; 14:192–199.
13. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological Society of North America Expert Consensus document on reporting chest CT findings related to COVID-19: endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiol Cardiothorac Imaging 2020; 2:e200152.
14. Ayubkhanii D, Khunti K, Nafiylian V, Maddox T, Humberstone B, Diamond I, Banerjee A. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021; 372:n2683.
15. Bidei B, Madhavan MV, Jinnem D, Chuchl T, Dreyfus L, Drigrin E, et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IU Ha, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 75:2950–2973.
16. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395:1417–1418.
17. Cicic F, Beretta L, Scandroglio AM, Colombo S, Landori G, Ruggeri A, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCOLTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 2020; 22:95–97.
18. Rovas A, Osiawie I, Buscher K, Sackard J, Tepasse PR, Fobker M, et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis 2021; 24:145–157.
19 Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7:e575–e582.
20 Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res 2020; 192:152–160.
21 Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther 2020; 5:293.
22 Drakos S, Chatzantonis G, Bieterbeck M, Evers G, Schulze AB, Mohr M, et al. Cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients. Sci Rep 2021; 11:15667.
23 Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27:601–615.
24 Ramadan MS, Bertolino L, Zampino R, Durante-Mangoni E; Monaldi Hospital Cardiovascular Infection Study Group. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. Clin Microbiol Infect 2021; 27:1250–1261.
25 Djalleb L, Riou L, Piliero N, Carabelli A, Vautrin E, Broisat A, et al. SPECT myocardial ischemia in the absence of obstructive CAD: contribution of the invasive assessment of microvascular dysfunction. J Nucl Cardiol 2018; 25:1017–1022.
26 Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368:473–474.
27 Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 2020; 26:842–844.